jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Conjunctival Biopsy

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of eye conjunctiva.

₹296₹423

30% OFF

Conjunctival Biopsy - Comprehensive Medical Test Information Guide

  • Why is it done?
    • Test Purpose: A conjunctival biopsy is a tissue sampling procedure that involves obtaining a small sample of tissue from the conjunctiva (the clear membrane covering the white part of the eye) for microscopic examination and laboratory analysis to identify infectious agents, malignancies, inflammatory conditions, or systemic diseases.
    • Primary Indications: Diagnosis of conjunctival tumors or suspected malignancies; investigation of chronic conjunctivitis of unknown etiology; suspected viral infections (including herpesviruses or adenovirus); identification of parasitic infections; diagnosis of systemic diseases with ocular manifestations; investigation of allergic or immunological conditions affecting the conjunctiva; detection of microbial pathogens including bacteria, fungi, or Chlamydia species.
    • Timing and Circumstances: Performed when conjunctival lesions are suspicious for malignancy; when standard diagnostic tests fail to identify the cause of persistent eye symptoms; when there is visible conjunctival abnormality requiring histological confirmation; during evaluation of ocular manifestations of systemic diseases; when screening for infectious agents not detected by standard testing methods; urgently in cases of suspected ocular lymphomas.
  • Normal Range
    • Reference Values: Conjunctival biopsy results are reported qualitatively rather than with numerical values. Normal findings include: healthy stratified squamous epithelium without atypia; absence of malignant cells; no abnormal inflammatory infiltrates; negative culture results for pathogenic organisms; normal conjunctival tissue architecture; appropriate vasculature without abnormalities.
    • Result Interpretation Categories: Negative/Normal - indicates benign findings with no pathological organisms or malignant cells detected; Positive - indicates presence of specific pathogens, malignant cells, or abnormal tissue architecture; Inconclusive - insufficient tissue sample or unclear findings requiring repeat biopsy.
    • Units and Reporting: Results reported as descriptive pathology findings; culture results reported as organism identification or 'no growth'; PCR results reported as positive/negative or quantitative viral load if applicable; histopathological findings documented with specific cell types and tissue architecture.
    • Normal vs. Abnormal: Normal findings represent healthy conjunctival tissue with intact epithelial layers, normal vasculature, and absence of infection or malignancy. Abnormal findings indicate presence of disease requiring specific treatment tailored to the identified pathology.
  • Interpretation
    • Malignancy Findings: Presence of atypical cells, dysplasia, or frank malignant cells indicates conjunctival tumor. Squamous cell carcinoma shows increased nuclear-to-cytoplasmic ratio, irregular nuclei, and increased mitotic activity. Lymphomas display abnormal lymphoid infiltrates. Melanoma presents with atypical melanocytes. Basal cell carcinoma shows nests of basaloid cells with peripheral palisading.
    • Infectious Findings: Positive cultures indicate specific bacterial, fungal, or parasitic infection requiring targeted antimicrobial therapy. Viral inclusions seen on microscopy suggest viral conjunctivitis. Chlamydial findings show characteristic intracytoplasmic inclusion bodies. PCR detection of viral DNA indicates active viral infection with quantitation possible.
    • Inflammatory and Immunological Findings: Increased eosinophils indicate allergic conjunctivitis; plasma cell infiltration suggests chronic inflammation; lymphocytic infiltration may indicate viral infection or autoimmune disease; immunoglobulin deposits detected by immunofluorescence indicate specific immune conditions.
    • Systemic Disease Manifestations: Ocular cicatricial pemphigoid shows subepithelial complement deposits; Stevens-Johnson syndrome displays epithelial necrosis and inflammatory infiltrate; sarcoidosis may show granulomatous infiltration; amyloidosis reveals characteristic staining patterns with Congo red.
    • Factors Affecting Results: Prior antimicrobial therapy may reduce culture sensitivity; inadequate sample size affects diagnostic accuracy; contamination during collection may result in false positives; timing of biopsy relative to infection affects pathogen detection; tissue preservation method impacts histological interpretation.
    • Clinical Significance: Positive malignancy findings necessitate immediate oncological consultation and treatment planning; infectious findings guide targeted therapy choice and duration; inflammatory findings may indicate need for systemic workup; results directly influence treatment decisions and patient prognosis.
  • Associated Organs
    • Primary Organ System: The eye, specifically the external eye and anterior segment including the conjunctiva (bulbar and palpebral surfaces), as well as the lacrimal drainage system which may be secondarily affected.
    • Commonly Associated Diseases: Conjunctival squamous cell carcinoma; conjunctival melanoma; ocular lymphomas; bacterial conjunctivitis (Staphylococcus, Streptococcus, Pseudomonas); viral conjunctivitis (herpes simplex, adenovirus); Chlamydial infection; trachoma; ocular cicatricial pemphigoid; Stevens-Johnson syndrome; allergic conjunctivitis; graft-versus-host disease; parasitic infections; sarcoidosis with ocular involvement.
    • Diagnostic Applications: Confirms diagnosis of conjunctival neoplasms for surgical planning; identifies causative organisms in resistant infections; establishes diagnosis of autoimmune ocular surface disease; aids in diagnosing systemic diseases with ocular manifestations; provides tissue for molecular testing including HPV status in malignancies; enables immunohistochemical analysis for lymphoma classification.
    • Potential Complications: Corneal abrasion from biopsy procedure; minimal bleeding usually self-limiting; infection at biopsy site (rare with proper technique); secondary ocular surface disease if biopsy involves extensive tissue removal; conjunctival scarring in rare cases; temporary conjunctival inflammation and irritation.
    • Related Systemic Manifestations: Abnormal biopsy findings may indicate systemic disease requiring further investigation including skin biopsy, lymph node assessment, or bone marrow biopsy for lymphomas; systemic infectious disease workup for disseminated infections; evaluation of autoimmune conditions affecting multiple organ systems.
  • Follow-up Tests
    • Tests for Malignancy Diagnosis: Orbital imaging (CT or MRI) to assess for intraocular extension; B-scan ultrasound for evaluation of posterior segment involvement; chest X-ray and CT to assess for metastatic disease; PET-CT scan for lymphomas or advanced malignancies; immunohistochemistry on biopsy sample for tumor classification; HPV testing for squamous cell carcinomas; sentinel lymph node biopsy for staging.
    • Tests for Infectious Disease: Blood cultures if systemic infection suspected; serology for viral infections (HSV, VZV, CMV); Chlamydial nucleic acid amplification testing (NAAT) of other sites; fungal blood cultures for systemic fungal disease; PCR for specific viral identification; antibiotic susceptibility testing based on culture results; repeat conjunctival swabs to assess treatment response.
    • Tests for Systemic Disease: Skin biopsy for ocular cicatricial pemphigoid or Stevens-Johnson syndrome confirmation; serum autoantibody panel (ANA, anti-BP180, anti-BP230); tissue transglutaminase (tTG) antibodies for celiac disease; angiotensin-converting enzyme (ACE) level and chest imaging for sarcoidosis; direct immunofluorescence on perilesional skin; systemic inflammatory markers (ESR, CRP).
    • Monitoring and Surveillance: Clinical examination of conjunctiva every 3-6 months following malignancy diagnosis; repeat conjunctival biopsy if recurrence suspected; photographic documentation of biopsy site for comparison; ocular surface disease assessment with Schirmer test and tear break-up time; periodic systemic assessments for metastatic disease or disease progression.
    • Complementary Testing: Tear film analysis for ocular surface disease; conjunctival impression cytology; slit-lamp photography; anterior segment optical coherence tomography (OCT); lacrimal gland biopsy if systemic disease suspected; complete eye examination including intraocular pressure measurement and dilated fundus examination.
  • Fasting Required?
    • Fasting Requirement: No - fasting is not required for conjunctival biopsy. This is a localized ophthalmic procedure that does not involve systemic anesthesia or gastrointestinal preparation.
    • Anesthesia Considerations: Procedure typically performed under topical anesthesia only (eye drops); no systemic sedation or general anesthesia required in routine cases; rarely, local infiltration anesthesia may be used for larger biopsies.
    • Medications - Pre-biopsy Instructions: Avoid anticoagulation medications (warfarin, apixaban, dabigatran) for 3-5 days prior if possible to reduce bleeding risk; discuss aspirin use with physician (may need to continue or hold based on indication); discontinue topical antibiotics or antibiotic ointments 24 hours before procedure to prevent interference with culture results; avoid topical anti-inflammatory medications for 48 hours prior; continue other systemic medications as directed.
    • Patient Preparation Requirements: Remove contact lenses on day of procedure; wash eyes gently with sterile saline morning of appointment; avoid eye makeup and contact lens insertion day of biopsy; arrange for transportation if sedation used; wear loose, comfortable clothing for easy arm access if bloodwork required; arrive with adequate time for informed consent discussion.
    • Post-procedure Instructions: Apply topical antibiotic ointment as prescribed; avoid rubbing or touching the biopsied eye; use protective eyeglasses or shield as directed; rest eyes for remainder of day; take prescribed analgesics for mild discomfort; avoid strenuous activities for 24-48 hours; do not resume contact lens wear until cleared by ophthalmologist (typically 1-2 weeks); attend follow-up appointment to assess healing and receive results.

How our test process works!

customers
customers